• Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

Duet pairs invention with scientific rigor to develop solutions that restore human health.

Duet BioTherapeutics is a clinical stage immuno-oncology company pioneering the development of bifunctional oligonucleotides to address “undruggable” targets such as STAT3. The company’s mission is to discover and develop therapeutic solutions that empower the human immune system to restore health, even when faced with seemingly intractable, treatment-resistant cancer. Duet integrates the management and clinical development of the immunotherapy assets of Scopus BioPharma and Olimmune, a company acquired by Scopus in June 2021, and founded by Marcin Kortylewski, Ph.D. and John Rossi, Ph.D.

The Duet Team

AllLeadership TeamScientific Advisory BoardBoard of Directors
Alan Horsager, Ph.D.

Alan Horsager, Ph.D.

President, CEO, & Director
Read Bio
Marcin Kortylewski, Ph.D.

Marcin Kortylewski, Ph.D.

Senior Scientific Advisor, Professor, & Co-founder of Olimmune
Read Bio
John Rossi, Ph.D.

John Rossi, Ph.D.

Professor and Co-Founder of MiNA & Dicerna
Read Bio
Nagy Habib

Nagy Habib

Professor & Co-Founder of MINA Therapeutics
Read Bio
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

© 2023 Duet BioTherapeutics. All rights reserved | Privacy Policy | Cookies Policy